Active ingredientDacarbazineCat. No. P-D003-001CAS 4342-03-4Family · Pharmaceutical analytical standards
Dacarbazine
An alkylating chemotherapy drug synthesised in 1959 in Alabama and approved in the United States in 1975: it is used for metastatic melanoma and, in the ABVD regimen, for Hodgkin lymphoma. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards and other impurities.
Did you know?It is a prodrug: it becomes active only in the liver, where it turns into MTIC, the molecule that attaches methyl groups to the DNA of tumour cells. It is on the WHO List of Essential Medicines.
Go to the active ingredient →Active ingredientDacarbazineCat. No. P-D003-001CAS 4342-03-4
Pharmacopoeial impurityDacarbazine EP Impurity ACat. No. P-D003-002CAS 4656-86-4
Pharmacopoeial impurityDacarbazine EP Impurity A (as Monohydrate)Cat. No. P-D003-003CAS 7151-03-3
Pharmacopoeial impurityDacarbazine EP Impurity A Sodium Salt Trihydrate (2-Azahypoxanthine Sodium Salt Trihydrate)Cat. No. P-D003-004
Pharmacopoeial impurityDacarbazine EP Impurity BCat. No. P-D003-005CAS 360-97-4
Pharmacopoeial impurityDacarbazine EP Impurity B HydrochlorideCat. No. P-D003-006CAS 72-40-2
Pharmacopoeial impurityDacarbazine EP Impurity CCat. No. P-D003-007CAS 1314929-56-0
Isotopically labelledDacarbazine-d6Cat. No. P-D003-008CAS 1185241-28-4
Impurity4-Oxo-4H-imidazo(4,5-d)-v-triazineCat. No. P-D003-009CAS 63907-29-9
ImpurityDacarbazine Lactose Adduct ImpurityCat. No. P-D003-010No product matches your search.
EDQM standards 3
The official European Pharmacopoeia standards for this family.
Reference substanceDacarbazine CRSEDQM code Y0000733Family DacarbazineImpurityDacarbazine EP impurity AEDQM code Y0000734Family DacarbazineImpurityDacarbazine impurity B CRSEDQM code Y0000735Family DacarbazineNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.